Vistagen Therapeutics Files 8-K
Ticker: VTGN · Form: 8-K · Filed: May 24, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K on 5/23, updating corporate info. Nothing major, just housekeeping.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on May 23, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at 343 Allerton Avenue, South San Francisco, California, 94080, with a phone number of (650) 577-3600. The company was incorporated in Nevada and previously operated under the names VistaGen Therapeutics, Inc. and Excaliber Enterprises, Ltd.
Why It Matters
This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Vistagen Therapeutics, Inc.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting corporate information and does not appear to contain significant new financial or operational developments.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- May 23, 2024 (date) — Date of earliest event reported
- 343 Allerton Avenue, South San Francisco, California, 94080 (location) — Principal executive offices
- Nevada (jurisdiction) — State of incorporation
- VistaGen Therapeutics, Inc. (company) — Former company name
- Excaliber Enterprises, Ltd. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Vistagen Therapeutics, Inc.?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of May 23, 2024.
Where are Vistagen Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California, 94080.
What is the telephone number for Vistagen Therapeutics, Inc.?
The telephone number is (650) 577-3600.
In which state was Vistagen Therapeutics, Inc. incorporated?
Vistagen Therapeutics, Inc. was incorporated in Nevada.
What were Vistagen Therapeutics, Inc.'s former company names?
The company was formerly known as VistaGen Therapeutics, Inc. and Excaliber Enterprises, Ltd.
Filing Stats: 483 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-23 17:54:34
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn20240523_8k.htm (8-K) — 22KB
- ex_679330.htm (EX-99.1) — 13KB
- v01.jpg (GRAPHIC) — 3KB
- 0001437749-24-018214.txt ( ) — 173KB
- vtgn-20240523.xsd (EX-101.SCH) — 3KB
- vtgn-20240523_def.xml (EX-101.DEF) — 11KB
- vtgn-20240523_lab.xml (EX-101.LAB) — 15KB
- vtgn-20240523_pre.xml (EX-101.PRE) — 11KB
- vtgn20240523_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On May 23, 2024, Vistagen Therapeutics, Inc. (the " Company ") announced that it will present posters highlighting fasedienol, the Company's investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder, and itruvone, the Company's investigational pherine candidate in Phase 2 development for the treatment of major depressive disorder, at the American Society of Clinical Psychopharmacology Conference in Miami Beach, Florida, from May 28 to 31, 2024. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits . (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated May 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: May 23, 2024 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer